---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-080483"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2022-07-18T23:59:59+00:00"
generated_at: "2026-06-24T13:42:13.481122+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celldex settles Kolltan merger litigation; agrees to up to $80M in milestone payments

## Summary
- Celldex pays $15M upfront; future milestones replaced with $12.5M on successful Phase II of CDX-0159 (barzolvolimab) and $52.5M on first regulatory approval.
- Litigation in Delaware Court of Chancery to be dismissed with prejudice; each side bears own fees.
- Prior milestone obligations under the 2016 Kolltan merger agreement are superseded; remaining payments at Celldex's election in cash or stock.
- Settlement releases all claims related to the merger agreement, including those in the lawsuit.

## SEC filing metadata
- accession: 0001104659-22-080483
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2022-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465922080483/0001104659-22-080483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465922080483/tm2221215d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-080483
- JSON: https://secwatch.observer/filing/0001104659-22-080483.json
- Plain text: https://secwatch.observer/filing/0001104659-22-080483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.